AUG 15, 2019
In this interview from ASRS 2019, Dr. David Boyer discusses patient characteristics that portend vision outcomes. He used data from the multicenter phase 3 HARBOR trial that included patients treated with as-needed or monthly ranibizumab for wet AMD. When comparing participants with good (>20/40) and bad (<20/40) visual outcomes, he noted that central foveal thickness poorly correlated with improvements in visual acuity. The best predictor of a good outcome, he found, was good baseline vision. In addition, the presence of intraretinal fluid appeared to be detrimental to final vision.
Relevant Financial Disclosures: Dr. Boyer is a consultant for Genentech.